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Summary This study evaluates the use of a multidrug resistance (MDR) modulator (verapamil) in combina-
tion with a standard dose of single-agent etoposide in relapsed or refractory paediatric malignancy. A total of
20 patients (median age 6.5 years) were treated with an infusion of verapamil (loading dose 0.1 mgkg-',
followed by continuous infusion 0.15mgkg-' h-') for 72 h. Etoposide was given daily (150mgm-2 day-') for
three doses (each over 1 h); the first dose was given 12 h into the verapamil infusion. Cardiovascular toxicity
was monitored by ECG and 2 hourly blood pressure and pulse recordings. Verapamil and norverapamil
plasma concentrations were measured daily. Disease response was assessed after two courses. A total of 29/35
treatment courses were given at the desired verapamil dose; five courses required a dose reduction owing to
cardiovascular toxicity. No patient required intensive monitoring. All patients who developed cardiovascular
toxicity were over 14 years old. There was no correlation between plasma verapamil or norverapamil
concentrations and toxicity. There were six partial responses (three rhabdomyosarcoma, three neuroblastoma)
after two courses, but because of variation in the dose and schedule of etoposide these cannot be une-
quivocally contributed to MDR reversal. In conclusion, a regimen using a continuous infusion of verapamil
combined with divided-dose etoposide is tolerable in children, and this strategy may be effective in refractory
neuroblastoma and rhabdomyosarcoma.
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The development of drug resistance during the treatment of
childhood cancer is the major limiting factor in the success of
chemotherapy. Although more than half of all children with
cancer can now be cured, some will have disease which is
refractory to multimodality treatment at presentation, and
others will develop resistance to previously effective agents.
Of the many described mechanisms of drug resistance the
phenomenon of multidrug resistance (MDR) is increasingly
recognised in both adult and paediatric practice (Chan et al.,
1993).
One ofthe first agents used as an MDR modulator in clinical
practice was verapamil. This drug is a potent vasodilator
with negative inotropic properties and is widely used in the
treatment of supraventricular tachyarrhythmias. Elimination
is largely by hepatic metabolism, with excretion of inactive
products in the urine and faeces (Scott et al., 1984).
Verapamil metabolism and conjugation result in the
accumulation of metabolites, including norverapamil, which
has some (minimal) vasodilator properties and is also active
against P-glycoprotein.
The effect of verapamil (and other calcium antagonists) on
drug efflux is independent of its action on either the-car-
diovascular system or calcium channels. Verapamil is nor-
mally given as a raecemic mixture of the L-isomer, which is
10-fold more effective as a calcium channel blocker and
hence more cardiotoxic, and the D-isomer, which is as
effective at reversing MDR in preclinical models (Bissett et
al., 1991; Scheithauer et al., 1993).
Verapamil concentrations of 3200 tg 1-' (6.6,LM) are
required to modulate MDR in vitro, although clinical
experience suggests that plasma concentrations of 300-500
ftgl l may be effective in adults and children. Verapamil
concentrations of 1800 g 1'- have been achieved during
clinical trials for MDR modulation, but almost all patients
experienced toxicity. Events attributable to verapamil toxicity
are largely cardiovascular, with first-degree heart block and
hypotension being the commonest.
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Second- and third-degree heart block may also occur, as
may arrhythmias or cardiac failure. The negative inotropic
effects are/greatly exacerbated by the concomitant use of
beta-blockers. Other side-effects include constipation, head-
aches, peripheral oedema and reversible changes in liver
enzymes.
There are few data regarding MDR reversal in childhood
tumours, and this is the first study to evaluate the combina-
tion of single-agent etoposide combined with verapamil.
Patients and methods
Eligibility criteria
Patients whose disease had relapsed after primary and in
some cases 'salvage' therapy or who had progressed through
standard therapy were eligible for the study. All had received
etoposide as part of initial chemotherapy; in most cases this
was within the previous 6 months, but if not the patient was
retreated with single-agent etoposide (450mgm-2 over 3
days) in order to confirm etoposide resistance before the
addition of verapamil.
Patients were considered ineligible for this study if they
had a previous history of clinical cardiac dysfunction or an
abnormal baseline electrocardiogram (ECG), if they had
received more than 400mgm2 anthracyclines (irrespective
of ECG), if they were receiving antihypertensives or digoxin
or had impaired liver function at entry.
The treatment protocol was approved by Royal Marsden
ethical committee, and informed written consent obtained
from the patient or their parent or guardian.
Twenty patients were recruited. Eighteen were children or
adolescents aged 10 months to 18 years; two adults with
'paediatric tumours' (rhabdomyosarcoma and Ewing's sar-
coma) were included. The age range was 10 months to 43
years (median age 6+ years); 15 of those treated were male.
Diagnosis and prior chemotherapy are listed in Table 1. Six
of the 20 patients had relapsed at previously involved sites
only, whereas the others had relapsed at multiple sites includ-
ing previously uninvolved areas.ModulatIon of MDR in padatrk malignancy
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Study design
All patients were designated to receive two courses of
verapamil and etoposide alone before full reassessment of
disease (Figure 1).
Verapamil was administered as a continuous infusion, star-
ting with a loading dose of 0.1 mg kg-' given over 15 min,
followed by continuous infusion of 3.6 mg kg-Iday-' (i.e.
0.15 mg kg-' h-') over the next 72 h.
Etoposide was given daily, the first dose 12 h after the start
of the verapamil infusion. The dose (150 mgmi2) was
repeated daily for 3 days and each dose was given over 1 h.
Patients treated thus do not require continuous cardiac
monitoring (Benson et al., 1985), and therefore monitoring
for potential cardiotoxicity was undertaken simply by
monitoring blood pressure and pulse every 2 h and by daily
ECG recording.
In the event of cardiac toxicity (most commonly bradycar-
dia with hypotension) the infusion was discontinued for 2 h
and then restarted. The verapamil dose was reduced by 25%
of the original if the ECG showed heart block or an arrhyth-
mia.
If a response occurred or if the disease was stable, vincris-
tine and actinomycin D were added for the third and subse-
quent courses. The courses were given 3 weeks apart unless
haematopoietic toxicity necessitated a delay.
Measurement ofverapamil andnorverapamil in plasma
Blood was taken daily for measurement of verapamil and
norverapamil in plasma, the first sample 12 h after the
verapamil infusion was started. All samples were taken from
a different central line lumen or peripheral line from that
used for the verapamil infusion. The blood samples were
collected into heparin and plasma separated by centrifugation
within 15 min of collection. The supernatant was stored at
-20C and transported in dry ice to the laboratory.
Verapamil and norverapamil were measured by high-
performance liquid chromatography (HPLC) with fluor-
escence detection (excitation wavelength 200 nm, no emission
filter; ABI model 980 fluorescence spectrophotometric detec-
tor, glass window). Sample or plasma standards (100 pl),
internal standard (aqueous benzoquinoline solution, 50IAl,
1 mgI1) and aqueous sodium hydroxide solution (50 il,
4 mol 1-') were added to 60 5-mm disposable glass test tubes
and the analytes extracted into methyl-tert.-butyl ether
(200tsl) after vortex mixing (30 s) and centrifugation (9950g,
3 min). A portion of the ethereal phase (70-100 pl) was
injected into the HPLC system (Rheodyne model 7125,
100 il loop) and the analytes resolved using a Spherisorb
S5SCX column (150 x 5 mm i.d.) and a mobile phase appar-
ent pH 0.15, measured using a glass electrode calibrated
against aqueous buffers) containing perchloric acid (0.2%,
v/v) in a mixture of methanol-acetonitrile-water (4:4:2).
This was delivered (flow rate 1.5 ml min-) using an ACS
series 300 isocratic pump. The method was calibrated using
standard solutions of verapamil and norverapamil (25, 50,
100, 200 and 500 S g I'-) prepared from methanolic stock
solutions (1 g 1-' free base) dissolved in newborn calf serum.
Two or three values for verapamil and norverapamil
plasma concentration were available for each treatment
Time
(h)
0 12 24 36 48 60 72
Verapamil infusion
(0.15 mg kg-' h-1)
Verapamil.loading +
dose (0.1 mg kg-')
Etoposide
(150 mg m-2)
Figure 1 Outline of verapamil and etoposide schedule.
Table I Details ofpatients, diagnosis and chemotherapy before entry on study
Patient Age in years
number Sex atpresentation Disease Prior chemotherapy
1 M 11 Hodgkin's disease ChlVPP, HOPE/bleomycin, melphalan/ABMT,
oral and intravenous etoposide
2 F 3 Wilms' tumour AVA, carboplatin, cyclophosphamide/etoposide
3 M 15 Ewing's sarcoma IVAd, IVA, oral etoposide
4 M 8 months Neuroblastoma OPEC/OJEC
5 F 6 Neuroblastoma OPEC/OJEC
6 F I Neuroblastoma OPEC/OJEC, melphalan/ABMT
7 F 4 Neuroblastoma OPEC/OJEC, carboplatin
8 M 3 Neuroblastoma OPEC/OJEC
9 M 4 Neuroblastoma OPEC/OJEC, melphalan/ABMT
10 M 6 Neuroblastoma OPEC/OJEC
11 F 4 Neuroblastoma OPEC/OJEC
12 M 15 Rhabdomyosarcoma SIOP MMT 89, melphalan/ABMT
13 M 4 Rhabdomyosarcoma JEB, IVA, melphalan/ABMT
14 M 26 Rhabdomyosarcoma IVAd, BEP
15 M 11 Acute lymphoblastic UKALL X D, UKALL RI,
leukaemia cyclophosphamide/etoposide
16 M 1 Rhabdomyosarcoma VACA, etoposide/ifosfamide
17 M 13 Rhabdomyosarcoma SIOP MMT 89, melphalan/ABMT
18 M 41 Ewing's sarcoma VA, IVAd, ifosfamide/doxorubicin, oral etoposide
19 M 18 Ewing's sarcoma Etoposide/cisplatin, IVAd, ifosfamide/etoposide
20 M 11 Osteosarcoma Cisplatin/doxorubicin, ifosfamide/etoposide
methotrexate
OPEC, vincristine, cisplatin, etoposide, cyclophosphamide; OJEC, vincristine, carboplatin, etoposide,
cyclophosphamide; ABMT, autologous bone marrow transplant; mIBG, metaiodobenzylguanidine; AVA,
doxorubicin, vincristine, actinomycin D; SIOP, Societe Internationale D'Oncologie Pediatrique; MMT 89,
carboplatin, epirubicin, vincristine, ifosfamide, actinomycin D, etoposide (regimen for metastatic
rhabdomyosarcomaaspartofmalignantmesenchymal tumourstudy);JEB,carboplatin,etoposide,bleomycin;IVA,
ifosfamide, vincristine, actinomycin D; IVAd, ifosfamide, vincristine, doxorubicin; BEP, bleomycin, etoposide,
cisplatin; VACA, vincristine, doxorubicin, cyclophosphamide, actinomycin D; VA, vincristine, actinomycin D;
ChlVPP, chlorambucil, vincristine, procarbazine, prednisolone; HOPE, doxorubicin, vincristine, prednisolone,
etoposide; UKALL X D, vincristine, asparaginase, prednisolone, doxorubicin, 6-thioguanine, methotrexate
etoposide, cytosine arabinoside, 6-mercaptopurine; UKALL RI, vincristine, asparaginase, dexamethasone,
epirubicin, 6-thioguanine, methotrexate, etoposide, cytosine arabinoside, 6-mercaptopurine, cyclophosphamide.Modulaton of MDR In padlatrk malignancy
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course once the patient had been receiving a continuous
infusion of verapamil for 12 h. The highest of these values is
termed the 'peak', the median verapamil concentration for
each patient in each course was calculated and termed the
'median' verapamil concentration.
Response evaluation
Disease status was assessed before and after each course by
whichever imaging modality proved to be most informative.
All patients included in this study had an assessable disease
site which could be easily followed by relatively non-invasive
techniques.
Responses were graded as partial (PR), mixed (MR), stable
(SD) or progressive disease (PD) or not evaluable (NE).
Partial response was defined as a 50% reduction or greater in
all measurable disease sites. Mixed response was defined as a
PR or better at one or more disease sites, with stable disease
at other sites. Stable disease was defined as up to a 50%
reduction, or less than 25% increase, in some or all
measurable disease sites. Progressive disease was defined as
an unequivocal (more than 25%) increase at existing disease
sites or the development of one or more new lesions.
4-5 times lower than the verapamil levels but followed
similar trends.
Effect ofverapamil level on acute toxicity
Neither peak nor median verapamil (or norverapamil) plasma
concentrations were correlated with observed toxicity.
A dose reduction was required in two treatment courses
owing to first-degree heart block in a patient who achieved a
peak verapamil concentration of greater than 300fig 1-; this
patient also experienced severe mucositis. Peak verapamil
concentrations of greater than 300 1ig 1' were measured after
ten treatment courses. No dose reductions were needed in the
nine treatment courses achieving a peak verapamil concentra-
tion of 200-300 tgl-', although transient first-degree heart
block was seen in one of these courses. Four of the 14
treatment courses with a peak verapamil concentration of
100-200 lgl- required a dose reduction owing to first-
degree heart block. One patient (number 3) was particularly
sensitive to verapamil and remained in first-degree heart
block throughout both courses of treatment despite having
the administered dose of verapamil dropped to 25%, and
only achieving a peak recorded verapamil concentration of
35 tg 1-' (median 26,pg 11).
Results
Toxicity
All patients tolerated verapamil treatment well. Several of the
common side-effects of verapamil, including constipation
peripheral oedema and headache, were not observed. Car-
diovascular (CVS) toxicity was manifested predominantly as
hypotension and first-degree heart block. No case of second-
or third-degree heart block or any other arrhythmia was seen
during the first two treatment courses. All five patients who
experienced CVS toxicity were over the age of 14 years. None
ofthese patients required intensive care or had to discontinue
the verapamil infusion permanently, though 4/5 required a
reduction in the verapamil dose (no patient under the age of
14 required a dose reduction). There was no apparent cor-
relation between CVS toxicity and prior exposure to car-
diotoxic drugs (though patients who had received large doses
of such drugs were excluded). Patient 18 developed a rash
which was attributed to the verapamil infusion during both
courses, one patient (number 5) developed severe throm-
bocytopenia with both courses, and patient 14 developed
severe mucositis with his first course. The occurrence of
thrombocytopenia and mucositis with etoposide given alone
at these doses is unusual, and may have been potentiated by
verapamil.
Plasma verapamil concentration
Twenty-nine courses of verapamil were given at the planned
dose. Owing to acute toxicity (occurring during the verapamil
infusion) two courses were given at 75%, two at 50% and
two at 25% of the planned dose.
Considerable intra- and inter-patient variation was ob-
served in plasma concentrations of both verapamil and
norverapamil at all dose levels (Figure 2). For example, patient
4 received two courses of 100% verapamil dose. The median
verapamil concentrations were 192pgml-l and 90 ,gml-l
for the first and second courses, and norverapamil concentra-
tions 17jigml-I and 35pigml'. Patient 17 had a dose
reduction from 100% verapamil on the first course to 75%
on the second course. Verapamil (median) concentrations
were 88 figml-l and 135 ptg ml-', and norverapamil 35ILg
ml-' and 70 Lgml-l for the first and second courses respec-
tively.
The highest peak verapamil concentration occurred in a
patient whose verapamil dose had been reduced because of
bradycardia, and the lowest occurred in a patient who never
tolerated more than 25% of the desired dose because of
toxicity. Plasma norverapamil concentrations were typically
Response to treatment
All patients had previously received etoposide as part of
multiagent chemotherapy regimens (Table I). However, the
dose and schedule of etoposide varied considerably between
these treatments. For example in OPEC or OJEC 200 mg
m-2 is given over 4 h, in JEB 120 mgm- is given over 1 h
for three doses and the rhabdomyosarcoma protocol 'MMT
89 Group E' gives 200mg m2 over 1 h daily for 3 days.
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Figure 2 Peak verapamil (a) and norverapamil (b) concentra-
tions achieved in relation to the percentage of planned verapamil
dose (29 courses).
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Table II Further details on patients who achieved a partial response following two courses ofverapamil and etoposide
Maximnum
Patient Timefrom end ofinitial Previous etoposide dose andschedule (intravenous concentration Duration ofresponsefrom
number treatment to relapse unless otherwise specified) verapamil (jugI-') end offirst two courses
4 Progressed on treatment 200 mgm2 per course, three courses 365 3 months
10 Progressed on treatment 200 mg m 2 per course, five courses 200 5 months
11 Progressed on treatment 200 mgm2 per course, seven courses 117 Continuing at 15 months
14 5 months 360 mg m2 per course, five courses 191 6 months
16 9 months 100mgm2 per day x 5 days, three courses 285 15 months
17 4 months 150 mgm2 per course for six courses, then 150 1 month
150mgm-2 per day x 3 days for two courses
Six of the 20 patients exhibited a partial response (three
rhabdomyosarcoma, three neuroblastoma), and two patients
(one acute lymphoblastic leukaemia and one Ewing's sar-
coma) had a mixed response. The mixed response in a child
with Ewing's consisted in regression of lung metastasis with
no change in local recurrence, and in a child with acute
lymphocytic leukaemia (ALL) and bulky nodal disease a
response in lymph node size but not in marrow disease was
seen.
All three children with neuroblastoma who responded
had previously failed to respond to 200 mg m2 per course
etoposide. While the three patients with rhabdomyosar-
coma had all previously responded to etoposide (various
schedules), the child who obtained a lasting benefit (15
months) from verapamil and etoposide (450 mg m-2 per
course) had previously relapsed following 500mg m2 per
course (Table II).
Relationship between verapamil concentration and response
There was no correlation between either the peak or median
concentration of verapamil or norverapamil and the response
to treatment.
Discussion
There is very little published work on the clinical modula-
tion of MDR in children, and to date three reversal agents
have been used. In 1985 Bessho et al. reported a trial
of oral diltiazem (1.69-4.83 mg kg-' day-' for 4 days) with
one bolus dose of vincristine (1.5 mg m-2) given on the
second day. Two children developed second-degree heart
block with bradycardia which was reversible on stopping the
diltiazem.
Continuous-intravenous verapamil has been used in chil-
dren (Cairo et al., 1989) in a regimen giving a bolus of
vinblastine (2 mgm-2) followed h later by a continuous
infusion of etoposide (200 mg m2 day-' for 5 days). A
verapamil infusion was started 24h before the vinblastine
bolus, with a loading dose of 0.15mgkg-' followed by a
maintenance infusion of 0.005 mg kg- min' for 144 h.
Heart block (first or second degree) was seen in five of the 11
courses, and inotropic support was needed in two courses.
Steady-state verapamil concentrations were above 400 glg '-1.
None of the patients achieved a complete response, however
all patients (except a child with hepatoblastoma) had a par-
tial response to one or both courses. Subsequently, all
patients developed progressive disease and died.
Verapamil has been widely evaluated as a resistance
modifier in adults with a range of malignant diseases. In
most cases high-dose racemic verapamil has been given by
continuous intravenous infusion. There are also a few reports
using oral racemic verapamil or D-verapamil. From work in
vitro it is known that verapamil concentrations between 1000
and 3000 g 1-' (2-6gM) are effective in the modulation of
resistance to vincristine or doxorubicin (Tsuruo et al., 1983;
Twentyman et al., 1986) in cell lines. Both verapamil and its
principal metabolite norverapamil are active in modulating
MDR in vitro (Merry et al., 1989), however norverapamil has
fewer cardiovascular effects (Neugebauer, 1978). In clinical
practice concentrations of up to 3000pg 11 can be achieved
(Ozols et al., 1987), although, more realistically, plasma con-
=centrations of 250-500 gl- can be maintained with little
toxicity (Benson et al., 1985). However, serum concentrations
do not accurately reflect tissue or tumour concentrations in
which drug levels may be higher (Hamann et al., 1983).
While it is generally assumed that a higher serum
verapamil level is more effective in modulating the MDR
phenotype, this is not consistently borne out by the results
(Ozols et al., 1987; Miller et al., 1991). This may be because
these do not reflect tissue or tumour levels, or because the
amount of verapamil required to modulate MDR in vivo is
less than that shown to be necessary in vitro.
D-Verapamil has been used in an attempt to overcome the
cardiovascular side-effects seen with the racemic agent fol-
lowing the observation that both optical isomers of
verapamil are equally effective in vitro (Gruber et al., 1988).
These studies (Bissett et al., 1991; Scheithauer et al., 1993)
suggest that, while D-verapamil is less cardiotoxic than the
racemic mixture, a significant number of patients develop
cardiovascular side-effects until the dose is dropped to
800mgday-' or less (resulting in a serum level of about
1000 ytg 1-1).
On the whole, the effect of MDR modulation in adult
patients has been disappointing, with small numbers of
patients showing responses. The most encouraging report is
of three responses in eight patients (seven with multiple
myeloma and one with lymphoma) who progressed on treat-
ment with VAD (continuous-infusion vincristine and dox-
orubicin with oral dexamethasone), and then went on to
receive VAD with the addition of a continuous infusion of
verapamil (Dalton et al., 1989).
The observed toxicity in this study was lower than that
seen in previous (adult) studies (Miller et al., 1991; Pennock
et al., 1991). This may in part be attributable to the lower
dose used, though patient selection and the age of our
patients is probably also important. The verapamil concen-
trations that were achieved have been reported to cause
significant cardiovascular toxicity in adults. It is unclear why
there should be such a large variation in observed plasma
verapamil concentrations between patients and also between
courses. There was no significant disturbance in renal or
hepatic function in any patient, few other drugs were
administered and they were similar in all cases. The only
obvious predictor for CVS toxicity was the age of the
patient: all of the patients over the age of 14 years developed
heart block. There were no features to indicate which
patients were likely to respond to the combination of
verapamil and etoposide. The relevance of MDR status
remains to be demonstrated.
The design of this study does not permit firm conclusions
to be drawn regarding reversal of etoposide resistance,
although in the three patients who responded having failed
on treatment this seems likely. Etoposide dose and schedule
was not, however, identical when given with and without
verapamil. Moreover, as etoposide kinetics was not deter-
mined a dose effect due to reduced clearance as seen with
cyclosporin cannot be excluded.
In conclusion, this study in patients with relapsed paediat-Modulation of MDR in paediatric malignancy x
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ric tumours has shown that a regimen using a continuous
infusion of verapamil combined with divided dose etoposide
is tolerable and that the toxicity is low and easily managed
without the need for intensive care or monitoring. Measured
plasma verapamil and norverapamil concentrations vary
between patients and courses even when the administered
dose is the same. There is no apparent correlation between
toxicity and either dose or plasma concentration of
verapamil. The major dose-limiting cardiovascular toxicity
seen in adult studies was mild in this study and restricted to
patients over the age of 14 years. Because of the lack of
effective new drugs for poor prognosis paediatric cancers,
there is an urgent need to evaluate novel strategies.
Verapamil and cyclosporin are candidates for randomised
study in, for example, metastatic sarcomas, combined with
etoposide or anthracyclines.
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